GOG 162 CISPLATIN & PACLITAXEL IN OVARIAN CANCER

GOG 162 顺铂

• 批准号: 6265170
• 负责人: STEVEN C PLAXE
• 金额: $ 1.15万
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN DIEGO
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6265170
• 关键词: blood chemistry; cis platinum compound; clinical research; combination cancer therapy; cytotoxicity; drug administration rate /duration; drug adverse effect; drug screening /evaluation; epithelium; human mortality; human subject; human therapy evaluation; injection /infusion; neoplasm /cancer chemotherapy; neoplasm /cancer classification /staging; neoplastic process; ovary neoplasms; paclitaxel

Compare the progression-free survival and frequency of response of 24 versus 96 hours paclitaxel influsions combined with cisplatin in stage III and IV epithelial ovarian cancer, determine the incidence and severity of adverse events, and examine the relationship between plasma concentrations and drug toxicity in 24 and 96 hour schedules.

比较III期和IV期上皮性卵巢癌患者24小时与96小时紫杉醇输注联合顺铂治疗的无进展生存率和应答频率，确定不良事件的发生率和严重程度，并检查24小时和96小时方案中血浆浓度与药物毒性之间的关系。